Paul Feuerstadt

3.1k total citations · 2 hit papers
98 papers, 1.7k citations indexed

About

Paul Feuerstadt is a scholar working on Infectious Diseases, Epidemiology and Surgery. According to data from OpenAlex, Paul Feuerstadt has authored 98 papers receiving a total of 1.7k indexed citations (citations by other indexed papers that have themselves been cited), including 62 papers in Infectious Diseases, 52 papers in Epidemiology and 36 papers in Surgery. Recurrent topics in Paul Feuerstadt's work include Clostridium difficile and Clostridium perfringens research (61 papers), Microscopic Colitis (43 papers) and Gastrointestinal motility and disorders (25 papers). Paul Feuerstadt is often cited by papers focused on Clostridium difficile and Clostridium perfringens research (61 papers), Microscopic Colitis (43 papers) and Gastrointestinal motility and disorders (25 papers). Paul Feuerstadt collaborates with scholars based in United States, Canada and Switzerland. Paul Feuerstadt's co-authors include Lawrence J. Brandt, Scott J. Boley, George F. Longstreth, Rohit Das, Sahil Khanna, Glenn Tillotson, Winnie W. Nelson, Olga C. Aroniadis, Paul Kligfield and Thomas Louie and has published in prestigious journals such as SHILAP Revista de lepidopterología, Gastroenterology and Hepatology.

In The Last Decade

Paul Feuerstadt

83 papers receiving 1.7k citations

Hit Papers

Efficacy and Safety of RBX2660 in PUNCH CD3, a Phase III,... 2022 2026 2023 2024 2022 2023 50 100 150
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Efficacy and Safety of RBX2660 in PUNCH CD3, a Phase III, Randomized, Double-Blind, Placebo-Controlled Trial with a Bayesian Primary Analysis for the Prevention of Recurrent Clostridioides difficile Infection
    2022 179 citations Sahil Khanna, Christine Lee et al. profile →
  2. The burden of CDI in the United States: a multifactorial challenge
    2023 73 citations Paul Feuerstadt, Glenn Tillotson et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Paul Feuerstadt United States 20 851 685 657 479 320 98 1.7k
Raseen Tariq United States 18 727 0.9× 295 0.4× 747 1.1× 222 0.5× 312 1.0× 76 1.4k
Denise Youngs United Kingdom 24 470 0.6× 624 0.9× 576 0.9× 190 0.4× 150 0.5× 44 1.5k
M R B Keighley United Kingdom 28 374 0.4× 1.6k 2.4× 532 0.8× 313 0.7× 187 0.6× 91 2.5k
Mark Schoeman Australia 23 527 0.6× 1.3k 1.9× 428 0.7× 966 2.0× 586 1.8× 58 2.3k
Uma K. Murthy United States 15 246 0.3× 468 0.7× 235 0.4× 297 0.6× 110 0.3× 43 927
Patricia P. Bloom United States 14 794 0.9× 261 0.4× 559 0.9× 230 0.5× 628 2.0× 46 1.4k
Ana-Maria Sîngeap Romania 15 160 0.2× 249 0.4× 469 0.7× 235 0.5× 87 0.3× 83 916
Ramsey M. Dallal United States 24 461 0.5× 1.1k 1.7× 561 0.9× 176 0.4× 139 0.4× 40 2.0k
Josep Maria Viver Spain 26 113 0.1× 1.1k 1.6× 1.9k 2.8× 664 1.4× 96 0.3× 39 2.8k
Vanessa Primeau Canada 6 629 0.7× 303 0.4× 763 1.2× 76 0.2× 107 0.3× 6 1.5k

Countries citing papers authored by Paul Feuerstadt

Since Specialization
Citations

This map shows the geographic impact of Paul Feuerstadt's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Paul Feuerstadt with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Paul Feuerstadt more than expected).

Fields of papers citing papers by Paul Feuerstadt

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Paul Feuerstadt. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Paul Feuerstadt. The network helps show where Paul Feuerstadt may publish in the future.

Co-authorship network of co-authors of Paul Feuerstadt

This figure shows the co-authorship network connecting the top 25 collaborators of Paul Feuerstadt. A scholar is included among the top collaborators of Paul Feuerstadt based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Paul Feuerstadt. Paul Feuerstadt is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Khanna, Sahil, Daniel Van Handel, Brian J. Clark, et al.. (2025). Prevention of recurrent Clostridioides difficile infection by fecal microbiota, live-jslm (REBYOTA ® ) administered via colonoscopy: 6-month data from the single-arm phase IIIb CDI-SCOPE trial. Therapeutic Advances in Gastroenterology. 18. 1128579720–1128579720.
3.
Allegretti, Jessica R., Paul Feuerstadt, W Knapple, et al.. (2025). Safety and Efficacy of Fecal Microbiota, Live-jslm (REBYOTA®), for the Prevention of Recurrent Clostridioides difficile Infection in Participants With Inflammatory Bowel Disease in PUNCH CD3-OLS. Inflammatory Bowel Diseases. 31(8). 2112–2122. 1 indexed citations
4.
Khanna, Sahil, Paul Feuerstadt, Daniel Van Handel, et al.. (2025). S2048 Significant and Durable Microbiome Restoration in a Phase 3 Trial of Fecal Microbiota, Live-JSLM for Recurrent Clostridioides difficile Infection When Administered by Colonoscopy. The American Journal of Gastroenterology. 120(10S2). S440–S440.
5.
6.
Feuerstadt, Paul, Jessica R. Allegretti, Erik R. Dubberke, et al.. (2024). Efficacy and Health-Related Quality of Life Impact of Fecal Microbiota, Live-jslm: A Post Hoc Analysis of PUNCH CD3 Patients at First Recurrence of Clostridioides difficile Infection. Infectious Diseases and Therapy. 13(1). 221–236. 7 indexed citations
7.
Boustany, Antoine, Paul Feuerstadt, & Glenn Tillotson. (2024). The 3 Ds: Depression, Dysbiosis, and Clostridiodes difficile. Advances in Therapy. 41(11). 3982–3995. 3 indexed citations
8.
Feuerstadt, Paul, et al.. (2024). Live biotherapeutic products: a capstone for prevention of recurrent Clostridiodes difficile infection. SHILAP Revista de lepidopterología. 3. 1399440–1399440. 2 indexed citations
9.
10.
Feuerstadt, Paul, et al.. (2023). Patient Perception of Route of Rectal Administration of Live Biotherapeutic Product for Recurrent Clostridioides difficile Infection. Patient Preference and Adherence. Volume 17. 2153–2159. 5 indexed citations
11.
Garey, Kevin W., Anne J Gonzales-Luna, Brittany Lapin, et al.. (2023). Assessment of Quality of Life Among Patients With Recurrent Clostridioides difficile Infection Treated with Investigational Oral Microbiome Therapeutic SER-109. JAMA Network Open. 6(1). e2253570–e2253570. 20 indexed citations
12.
Lee, Christine, Thomas Louie, Adam Charles Harvey, et al.. (2023). Safety of fecal microbiota, live-jslm (REBYOTA™) in individuals with recurrent Clostridioides difficile infection: data from five prospective clinical trials. Therapeutic Advances in Gastroenterology. 16. 1108357253–1108357253. 52 indexed citations
13.
14.
Sims, Matthew, Michael Silverman, Thomas Louie, et al.. (2023). Integrated efficacy analysis from phase 3 studies of investigational microbiome therapeutic, SER-109, in recurrent Clostridioides difficile infection. SHILAP Revista de lepidopterología. 3(S2). s5–s5. 1 indexed citations
15.
Feuerstadt, Paul & Kerry L. LaPlante. (2023). Efficacy and Practical Implementation of Fecal Microbiota Spores, Live-BRPK: A Novel Approach for Preventing Recurrent Clostridioides difficile Infection. The American Journal of Gastroenterology. 119(1S). S22–S26. 2 indexed citations
16.
17.
Tillotson, Glenn, et al.. (2022). Microbiota-Based Live Biotherapeutic RBX2660 for the Reduction of Recurrent Clostridioides difficile Infection in Older Adults With Underlying Comorbidities. Open Forum Infectious Diseases. 10(1). ofac703–ofac703. 8 indexed citations
18.
Feuerstadt, Paul, Simon Hong, & Lawrence J. Brandt. (2019). Chronic Rifaximin Use in Cirrhotic Patients Is Associated with Decreased Rate of C. difficile Infection. Digestive Diseases and Sciences. 65(2). 632–638. 8 indexed citations
19.
Feuerstadt, Paul & Lawrence J. Brandt. (2010). Colon Ischemia: Recent Insights and Advances. Current Gastroenterology Reports. 12(5). 383–390. 44 indexed citations
20.
Feuerstadt, Paul, Jordan J. Karlitz, Hatef Massoumi, et al.. (2009). Effectiveness of hepatitis C treatment with pegylated interferon and ribavirin in urban minority patients†. Hepatology. 51(4). 1137–1143. 53 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Raseen Tariq Breakdown of academic impact, for papers by Denise Youngs Breakdown of academic impact, for papers by M R B Keighley Breakdown of academic impact, for papers by Mark Schoeman Breakdown of academic impact, for papers by Uma K. Murthy Breakdown of academic impact, for papers by Patricia P. Bloom Breakdown of academic impact, for papers by Ana-Maria Sîngeap Breakdown of academic impact, for papers by Ramsey M. Dallal Breakdown of academic impact, for papers by Josep Maria Viver Breakdown of academic impact, for papers by Vanessa Primeau
Rankless by CCL
2026